Search

Displaying results 1251 - 1260 of 3180 in total
  1. Drug

    Relutrigine

    go.drugbank.com/drugs/DB21614
    Investigational

    Relutrigine is under investigation in clinical trial NCT07010471 (A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine).

  2. Drug

    Susoctocog alfa

    go.drugbank.com/drugs/DB11606
    ApprovedInvestigational

    Intravenous susoctocog alfa is a recombinant, B-domain deleted, porcine sequence antihaemophilic factor VIII (FVIII) product that has recently been approved for the treatment of bleeding episodes in adults with acquired haemophilia A (AH...

  3. Drug

    Nanoparticle Epirubicin

    go.drugbank.com/drugs/DB16248
    Investigational

    Nanoparticle Epirubicin is under investigation in clinical trial NCT03168061 (Dose-escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma).

  4. Drug

    Mesalazine

    go.drugbank.com/drugs/DB00244
    ApprovedInvestigational

    An anti-inflammatory agent, structurally related to the salicylates and non-steroidal anti-inflammatory drugs like acetylsalicylic acid, which is active in inflammatory bowel disease . Although demonstrably effective in treating and main...

    Synonyms: p-Aminosalicylsaeure
  5. Drug

    SGN-15

    go.drugbank.com/drugs/DB05818
    Investigational

    SGN-15 is studied in the treatment of cancer. It combines a monoclonal antibody with the anticancer drug doxorubicin. Monoclonal antibodies are substances that are made in the laboratory and that can locate and bind to cancer cells. Doxo...

  6. Drug

    Anpocogin

    go.drugbank.com/drugs/DB06552
    Investigational

    Recombinant nematode anticoagulant protein c2 (rNAPc2) is a specific inhibitor of tissue factor (TF)/factor VIIa complex with novel antithrombotic activity.

  7. Drug

    Cobalamin

    go.drugbank.com/drugs/DB14098
    ApprovedInvestigational

    Mixtures: Folika-NC
  8. Drug

    SF1126

    go.drugbank.com/drugs/DB05210
    Investigational

    SF1126 is an integrin-targeted PI3 kinase inhibitor.

  9. Drug

    ALKS 27

    go.drugbank.com/drugs/DB05752
    Experimental

    Study showed that ALKS 27 was well-tolerated over a wide dose range, with no dose-limited effects observed.

  10. Drug

    Carbidopa

    go.drugbank.com/drugs/DB00190
    ApprovedInvestigational

    Carbidopa presents a chemical denomination of N-amino-alpha-methyl-3-hydroxy-L-tyrosine monohydrate.

    Mixtures: LEVOCAENT-NX 100/25/200, LEVOCAENT-NX 100/25/200